Karin Fjordén

1 – 10 of 10

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/med-kry?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

2022
Mark Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
Fjordén, Karin ^LU ; Ekberg, Sara ; Kuric, Nevzeta ; Smedby, Karin E. ; Lagerlöf, Ingemar ; Larsen, Thomas S. ; Jørgensen, Judit M. ; de Nully Brown, Peter and Jerkeman, Mats ^LU (2022) In British Journal of Haematology 196(2). p.437-440
- Contribution to journal › Letter
2016
Mark Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma : a Nordic Lymphoma Group study
Pauly, F. ^LU ; Fjordén, K. ^LU ; Leppä, S. ; Holte, H. ; Björkholm, M. ; Fluge ; Møller Pedersen, L. ; Eriksson, M. ^LU ; Isinger-Ekstrand, A. ^LU and Borrebaeck, C. A.K. ^LU , et al. (2016) In Blood Cancer Journal 6(11). p.501-501
- Contribution to journal › Article
2015
Mark Prognostic Markers and Mechanisms of Chemotherapy Resistance in Diffuse Large B-cell Lymphoma
Fjordén, Karin ^LU (2015) In Lund University Faculty of Medicine Doctoral Dissertation Series 2015:16.
- Thesis › Doctoral thesis (compilation)
2014
Mark Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma.
Taskinen, Minna ; Louhimo, Riku ; Koivula, Satu ; Chen, Ping ; Rantanen, Ville ; Holte, Harald ; Delabie, Jan ; Karjalainen-Lindsberg, Marja-Liisa ; Björkholm, Magnus and Fluge, Oystein , et al. (2014) In PLoS ONE 9(3).
- Contribution to journal › Article
2013
Mark The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.
Ageberg, Malin ^LU ; Fjordén, Karin ^LU ; Relander, Thomas ^LU and Drott, Kristina ^LU (2013) In American Journal of Translational Research 5(2). p.170-183
- Contribution to journal › Article
2012
Mark Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma
Fjordén, Karin ^LU ; Joost, Patrick ^LU ; Ehinger, Mats ^LU ; Edén, Patrik ^LU ; Jerkeman, Mats ^LU ; Cavallin-Ståhl, Eva ^LU and Linderoth, Johan ^LU (2012) In Leukemia & Lymphoma 53(9). p.1764-1768
- Contribution to journal › Article
Mark High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
Riihijarvi, Sari ; Nurmi, Heidi ; Holte, Harald ; Bjorkholm, Magnus ; Fluge, Oystein ; Pedersen, Lars Moller ; Fjordén, Karin ^LU ; Jerkeman, Mats ^LU ; Eriksson, Mikael ^LU and Leppa, Sirpa (2012) In European Journal of Haematology 89(5). p.395-402
- Contribution to journal › Article
2011
Mark Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
Ageberg, Malin ^LU ; Fjordén, Karin ^LU ; Lindén, Ola ^LU ; Linderoth, Johan ^LU ; Jerkeman, Mats ^LU and Drott, Kristina ^LU (2011) In Experimental Cell Research 317. p.1179-1191
- Contribution to journal › Article
2010
Mark Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
Riihijarvi, Sari ; Koivula, Satu ; Nyman, Heidi ; Fjordén, Karin ^LU ; Jerkeman, Mats ^LU and Leppa, Sirpa (2010) In Modern Pathology 23(5). p.686-693
- Contribution to journal › Article
Mark CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
Fjordén, Karin ^LU ; Linderoth, Johan ^LU ; Nyman, Heidi ; Ehinger, Mats ^LU ; Joost, Patrick ^LU ; Bendahl, Pär-Ola ^LU ; Leppä, Sirpa and Jerkeman, Mats ^LU (2010) In Leukemia & Lymphoma 51. p.1643-1648
- Contribution to journal › Article